MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)
MEDIROM Healthcare Technologies (NASDAQ: MRM) announced that Yasuhiro Hayami, Chief Business Officer of MEDIROM Mother Labs, has made a second investment in Mother Labs' Series A financing. The investment values Mother Labs at a pre-money valuation of JPY9 billion (approximately US$60 million) as of March 13, 2025.
This follow-up investment comes after Mr. Hayami's initial Series A investment in December 2024. As a committed senior executive, Hayami shares MEDIROM's corporate philosophy, vision, and commitment to future growth potential. His background includes founding INIT Co., in 1996, serving as Executive Officer at transcosmos inc. in 2004, and founding Wise, Inc. in 2014. In 2024, he was appointed Chairman of MEDIROM Rehab Solutions and Chief Business Officer of MEDIROM Mother Labs.
MEDIROM Healthcare Technologies (NASDAQ: MRM) ha annunciato che Yasuhiro Hayami, Chief Business Officer di MEDIROM Mother Labs, ha effettuato un secondo investimento nel finanziamento di Serie A di Mother Labs. L'investimento valuta Mother Labs con una valutazione pre-money di JPY9 miliardi (circa 60 milioni di dollari USA) al 13 marzo 2025.
Questo investimento di follow-up arriva dopo il primo investimento di Hayami nella Serie A avvenuto a dicembre 2024. Come un dirigente senior impegnato, Hayami condivide la filosofia aziendale, la visione e l'impegno di MEDIROM per il potenziale di crescita futura. La sua carriera include la fondazione di INIT Co. nel 1996, il ruolo di Executive Officer presso transcosmos inc. nel 2004 e la fondazione di Wise, Inc. nel 2014. Nel 2024, è stato nominato Presidente di MEDIROM Rehab Solutions e Chief Business Officer di MEDIROM Mother Labs.
MEDIROM Healthcare Technologies (NASDAQ: MRM) anunció que Yasuhiro Hayami, Director de Negocios de MEDIROM Mother Labs, ha realizado una segunda inversión en la financiación de Serie A de Mother Labs. La inversión valora a Mother Labs con una valoración pre-money de JPY9 mil millones (aproximadamente 60 millones de dólares estadounidenses) a partir del 13 de marzo de 2025.
Esta inversión de seguimiento se produce tras la inversión inicial de Hayami en la Serie A en diciembre de 2024. Como un ejecutivo senior comprometido, Hayami comparte la filosofía corporativa, la visión y el compromiso de MEDIROM con el potencial de crecimiento futuro. Su trayectoria incluye la fundación de INIT Co. en 1996, su trabajo como Director Ejecutivo en transcosmos inc. en 2004 y la fundación de Wise, Inc. en 2014. En 2024, fue nombrado Presidente de MEDIROM Rehab Solutions y Director de Negocios de MEDIROM Mother Labs.
MEDIROM Healthcare Technologies (NASDAQ: MRM)은 Yasuhiro Hayami가 MEDIROM Mother Labs의 최고 비즈니스 책임자로서 Mother Labs의 시리즈 A 자금 조달에 두 번째 투자를 했다고 발표했습니다. 이 투자는 Mother Labs의 사전 평가액을 JPY9억 엔 (약 6천만 달러)으로 평가합니다. 2025년 3월 13일 기준입니다.
이 후속 투자는 Hayami가 2024년 12월에 시리즈 A에 처음 투자한 이후에 이루어졌습니다. 헌신적인 고위 경영진으로서 Hayami는 MEDIROM의 기업 철학, 비전 및 미래 성장 잠재력에 대한 헌신을 공유합니다. 그의 경력에는 1996년 INIT Co. 설립, 2004년 transcosmos inc.에서의 임원직, 2014년 Wise, Inc. 설립 등이 포함됩니다. 2024년에는 MEDIROM Rehab Solutions의 회장과 MEDIROM Mother Labs의 최고 비즈니스 책임자로 임명되었습니다.
MEDIROM Healthcare Technologies (NASDAQ: MRM) a annoncé que Yasuhiro Hayami, Directeur Commercial de MEDIROM Mother Labs, a réalisé un second investissement dans le financement de série A de Mother Labs. Cet investissement valorise Mother Labs à une évaluation pré-money de JPY9 milliards (environ 60 millions de dollars américains) au 13 mars 2025.
Ce nouvel investissement fait suite à l'investissement initial de M. Hayami dans la série A en décembre 2024. En tant que cadre supérieur engagé, Hayami partage la philosophie d'entreprise, la vision et l'engagement de MEDIROM envers le potentiel de croissance future. Son parcours inclut la fondation d'INIT Co. en 1996, un poste de cadre chez transcosmos inc. en 2004, et la fondation de Wise, Inc. en 2014. En 2024, il a été nommé Président de MEDIROM Rehab Solutions et Directeur Commercial de MEDIROM Mother Labs.
MEDIROM Healthcare Technologies (NASDAQ: MRM) gab bekannt, dass Yasuhiro Hayami, Chief Business Officer von MEDIROM Mother Labs, eine zweite Investition in die Series A-Finanzierung von Mother Labs getätigt hat. Die Investition bewertet Mother Labs mit einer Pre-Money-Bewertung von JPY9 Milliarden (ca. 60 Millionen US-Dollar) zum 13. März 2025.
Diese Folgeinvestition erfolgt nach Hayamis erster Investition in die Series A im Dezember 2024. Als engagierter leitender Angestellter teilt Hayami die Unternehmensphilosophie, Vision und das Engagement von MEDIROM für zukünftiges Wachstumspotenzial. Zu seinem Werdegang gehört die Gründung von INIT Co. im Jahr 1996, die Tätigkeit als Executive Officer bei transcosmos inc. im Jahr 2004 und die Gründung von Wise, Inc. im Jahr 2014. Im Jahr 2024 wurde er zum Vorsitzenden von MEDIROM Rehab Solutions und Chief Business Officer von MEDIROM Mother Labs ernannt.
- Executive's second investment demonstrates strong internal confidence in company's growth potential
- High pre-money valuation of JPY9 billion (US$60 million) for Mother Labs subsidiary
- None.
Insights
The additional investment by Mother Labs' own Chief Business Officer in the Series A financing round represents a noteworthy vote of confidence from a key insider. With Mother Labs valued at
This valuation disparity raises important questions about MEDIROM's overall market valuation relative to its subsidiary. If Mother Labs'
The financing structure indicates MEDIROM continues developing its multi-layered business approach with separate capital raises for subsidiaries. While this executive's personal investment shows internal belief in Mother Labs' potential, the exact investment amount remains undisclosed, making it difficult to gauge the significance of this transaction beyond the symbolic support.
For investors, this presents a complex valuation puzzle. The disclosed pre-money valuation potentially signals future upside if Mother Labs succeeds and MEDIROM maintains substantial ownership, but the lack of specific details around ownership percentages and capitalization structure limits comprehensive analysis of how this specifically translates to MEDIROM shareholder value.
This follow-on investment by Mr. Hayami represents a strategic continuity signal in Mother Labs' development trajectory. His December 2024 initial investment followed by this second round demonstrates sustained confidence rather than a one-time optimistic bet.
The pre-money valuation of
From a corporate governance perspective, having a C-suite executive personally invested creates alignment between management incentives and corporate outcomes. However, this arrangement also introduces potential conflicts that require careful oversight - Mr. Hayami now serves dual roles as both executive and investor, potentially complicating decision-making regarding resource allocation and strategic priorities.
The announcement notably lacks details on the size of investment, percentage ownership, and implications for MEDIROM's consolidated control over the subsidiary. This Series A suggests Mother Labs is transitioning from early-stage development toward operational expansion, but without disclosure of the capital deployment strategy, investors cannot adequately assess potential returns or timeline to materialization.
This multi-layered corporate structure with separately financed subsidiaries creates both opportunities for focused investment and challenges for overall corporate coherence that investors should monitor closely.
TOKYO, March 13, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that Yasuhiro Hayami, Chief Business Officer of MEDIROM Mother Labs Inc. (“Mother Labs”), a subsidiary of the Company, has made a second investment in Mother Labs’ Series A financing at a pre-money valuation of JPY9 billion (as of March 13, 2025, approximately US
Background of Executive Officer
Yasuhiro Hayami
Chief Business Officer (CBO), MEDIROM MOTHER Labs Inc.
Career Summary
- 1996 Established INIT Co., Ltd. and assumed the position of Representative Director
- 2004 Executive Officer of transcosmos inc.
- 2014 Founder of Wise, Inc.
- 2024 Appointed Chairman of the Board of MEDIROM Rehab Solutions, Inc.
- 2024 Chief Business Officer of MEDIROM MOTHER Labs
No Offer or Solicitation
This press release and the information contained herein are not, and do not, constitute an offer to sell any securities or a solicitation of an offer to buy any securities in the United States or any other state or jurisdiction.
Forward-Looking Statements Regarding MEDIROM
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity.
More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.
ABOUT MEDIROM MOTHER Labs Inc.
A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), Mother Labs focuses on the health-tech sector. The company’s core activities include the “Specific Health Guidance Program” offered through the “Lav” health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc.
MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web https://medirom.co.jp/en
Contact: ir@medirom.co.jp
MEDIROM MOTHER Labs Inc.
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
MOTHER Bracelet is the world’s first* 24/7 recharge-free smart tracker. It uses innovative technology from a Silicon Valley tech company that allows for power generation based on temperature differences between body and surrounding air. The recharge-free feature eliminates the risk of data loss when a device is taken off for recharge. MOTHER Bracelet records five basic metrics: heart rate, calories burned, body surface temperature, step count, and sleep.
Official Website: https://mother-bracelet.com
* The first activity tracker that does not require recharging through use of the Seebeck effect, according to ESP Research Institute (July 3, 2021).
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d463ff2b-5922-4732-95ff-687bb2916296
FAQ
What is the pre-money valuation of MEDIROM Mother Labs in the Series A financing round?
When did Yasuhiro Hayami make his first investment in MRM's Mother Labs Series A financing?
What positions does Yasuhiro Hayami currently hold at MEDIROM companies?
What is the significance of the second Series A investment for MRM shareholders?
